clinical trial · NCT03213457
A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain
AbbVie·phase3·completed·n = 681
EndometriosisEstradiol/Norethindrone AcetatePlacebo for ElagolixElagolixPlacebo for E2/NETA
brief summary
The objective of this study is to evaluate safety and efficacy of elagolix in the management of moderate to severe endometriosis-associated pain in adult premenopausal female participants including the safety and efficacy of elagolix in combination with concomitant hormonal add-back therapy.
started
Jul 7, 2017
primary completion
Mar 27, 2020
completion
Dec 6, 2023
last updated
Dec 20, 2024
official title
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination With Estradiol/Norethindrone Acetate in Subjects With Moderate to Severe Endometriosis-Associated Pain
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol